Roth Capital Reiterates Buy On TG Therapeutics Following Clinical Study Initiation
TG Therapeutics (TGTX) announced the initiation of a novel three drug combination study assessing the chemo-free combination of TG-1101 + TGR-1202 + Imbruvica. This study will be added as a component of the ongoing Phase I study of the combination of TG-1101 and TGR-1202. This triple chemo-free combination study has the potential to represent the beginning of the shift from chemobased oncology therapies to target-based, chemo-free approaches to cancer treatment.
In reaction to the study initiation, Roth Capital analyst Joseph Pantginis today issued a note in which he reiterated a Buy rating on TGTX stock with a $25 price target.
Pantginis wrote, “This study will be the first time combination of a BTK inhibitor (Imbruvica) with a PI3K-delta inhibitor (TGR-1202). We believe this triple chemo-free combination study is signaling the future direction of cancer therapy, one in which targeted therapies will represent the main therapeutic paradigm for cancer treatment. We believe this combination study will appeal to many oncologists who wish to have options for chemo-free and therefore less toxic options for treating their patients. With target-based options, the toxicity profile diminishes significantly, although adverse events will still be part of the treatment, but we believe that in the case of drugs such as those used in this new combination trial, the safety profile will make them more favorable.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Joseph Pantginis has a total average return of -5.8% and a 40.8% success rate. Pantginis has a -11.8% average return when recommending TGTX, and is ranked #3171 out of 3242 analysts.